{"date":"2025-09-17","count":10,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-1271-2025-09-17-1812-1aomjka","company_id":"1271","company":"晨暉生技","market":"興櫃","industry":"生技醫療","date":"2025-09-17","time":"18:12:03","subject":"公告本公司買回庫藏股期間屆滿及執行情形","clause":"第41款","fact_date":"2025-09-17","cite_as":"公開資訊觀測站重大訊息：晨暉生技（1271），2025-09-17 18:12，「公告本公司買回庫藏股期間屆滿及執行情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7762-2025-09-17-1747-qmd25j","company_id":"7762","company":"吉晟生","market":"興櫃","industry":"生技醫療","date":"2025-09-17","time":"17:47:41","subject":"公告本公司取得簽證會計師內部控制專案審查報告","clause":"第25款","fact_date":"2025-09-17","cite_as":"公開資訊觀測站重大訊息：吉晟生（7762），2025-09-17 17:47，「公告本公司取得簽證會計師內部控制專案審查報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7790-2025-09-17-1657-17up2wc","company_id":"7790","company":"思必瑞特","market":"興櫃","industry":"生技醫療","date":"2025-09-17","time":"16:57:43","subject":"公告本公司董事會決議員工認股權憑證轉換普通股之增資基準日","clause":"第9款","fact_date":"2025-09-17","cite_as":"公開資訊觀測站重大訊息：思必瑞特（7790），2025-09-17 16:57，「公告本公司董事會決議員工認股權憑證轉換普通股之增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7790-2025-09-17-1653-g37hp6","company_id":"7790","company":"思必瑞特","market":"興櫃","industry":"生技醫療","date":"2025-09-17","time":"16:53:50","subject":"思必瑞特董事會決議召開114年第二次股東臨時會公告","clause":"第32款","fact_date":"2025-09-17","cite_as":"公開資訊觀測站重大訊息：思必瑞特（7790），2025-09-17 16:53，「思必瑞特董事會決議召開114年第二次股東臨時會公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4168-2025-09-17-1633-18xptfa","company_id":"4168","company":"醣聯","market":"上櫃","industry":"生技醫療","date":"2025-09-17","time":"16:33:31","subject":"公告本公司現金增資認股基準日及相關事宜(補充公告發行價格)","clause":"第11款","fact_date":"2025-09-17","cite_as":"公開資訊觀測站重大訊息：醣聯（4168），2025-09-17 16:33，「公告本公司現金增資認股基準日及相關事宜(補充公告發行價格)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6467-2025-09-17-1604-1v20vp9","company_id":"6467","company":"泰合","market":"興櫃","industry":"生技醫療","date":"2025-09-17","time":"16:04:31","subject":"公告本公司董事會決議辦理現金增資發行新股案","clause":"第9款","fact_date":"2025-09-17","cite_as":"公開資訊觀測站重大訊息：泰合（6467），2025-09-17 16:04，「公告本公司董事會決議辦理現金增資發行新股案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6576-2025-09-17-1559-rauvo7","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2025-09-17","time":"15:59:06","subject":"本公司藥物製造部門主管異動","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2025-09-17 15:59，「本公司藥物製造部門主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4743-2025-09-17-1554-1tt2k1l","company_id":"4743","company":"合一","market":"上櫃","industry":"生技醫療","date":"2025-09-17","time":"15:54:34","subject":"公告本公司Anti-CεmX單株抗體(FB825)取得泰國發明專利","clause":"第53款","fact_date":"2025-09-17","cite_as":"公開資訊觀測站重大訊息：合一（4743），2025-09-17 15:54，「公告本公司Anti-CεmX單株抗體(FB825)取得泰國發明專利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6576-2025-09-17-1548-132dblb","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2025-09-17","time":"15:48:22","subject":"公告本公司董事會決議調整發行114年國內第一次有擔保轉換公司債","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2025-09-17 15:48，「公告本公司董事會決議調整發行114年國內第一次有擔保轉換公司債」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6576-2025-09-17-1427-14xupvz","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2025-09-17","time":"14:27:28","subject":"公告本公司董事會決議辦理114年第1次私募普通股之定價暨增資基準日等相關事宜","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2025-09-17 14:27，「公告本公司董事會決議辦理114年第1次私募普通股之定價暨增資基準日等相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}